NASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis $1.89 +0.02 (+1.07%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.88▼$1.9550-Day Range$1.63▼$15.2952-Week Range$1.55▼$20.22Volume619,470 shsAverage Volume505,059 shsMarket Capitalization$93.97 millionP/E RatioN/ADividend YieldN/APrice Target$9.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get HilleVax alerts: Email Address HilleVax MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside386.8% Upside$9.20 Price TargetShort InterestHealthy7.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 5 Articles This WeekInsider TradingSelling Shares$193,766 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.58) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector182nd out of 936 stocksBiological Products, Except Diagnostic Industry20th out of 154 stocks 4.0 Analyst's Opinion Consensus RatingHilleVax has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageHilleVax has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about HilleVax's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.28% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently decreased by 26.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLVX. Previous Next 2.9 News and Social Media Coverage News SentimentHilleVax has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for HilleVax this week, compared to 1 article on an average week.Search Interest9 people have searched for HLVX on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows4 people have added HilleVax to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,766.00 in company stock.Percentage Held by Insiders71.10% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HilleVax's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for HilleVax are expected to grow in the coming year, from ($2.58) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHilleVax has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about HilleVax's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About HilleVax Stock (NASDAQ:HLVX)HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Read More HLVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLVX Stock News HeadlinesJuly 26 at 10:25 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVXJuly 24 at 8:00 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVXJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVXJuly 19, 2024 | globenewswire.comHilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVXJuly 14, 2024 | globenewswire.comHilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVXJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVXJuly 9, 2024 | globenewswire.comHilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 8, 2024 | investorplace.comWhy Is HilleVax (HLVX) Stock Down 87% Today?July 8, 2024 | globenewswire.comHilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in InfantsMay 10, 2024 | msn.comHilleVax GAAP EPS of -$0.97 misses by $0.12May 10, 2024 | finance.yahoo.comHilleVax Inc (HLVX) Reports Increased Q1 Losses, Misses Analyst Earnings ExpectationsMay 10, 2024 | investorplace.comHLVX Stock Earnings: HilleVax Misses EPS for Q1 2024May 9, 2024 | finance.yahoo.comHilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressApril 7, 2024 | investing.comHillevax director Aditya Kohli sells shares worth over $264kSee More Headlines Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HLVX CUSIPN/A CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$9.20 High Stock Price Target$34.00 Low Stock Price Target$2.00 Potential Upside/Downside+386.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,570,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.18% Return on Assets-43.75% Debt Debt-to-Equity Ratio0.11 Current Ratio10.92 Quick Ratio10.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book0.34Miscellaneous Outstanding Shares49,720,000Free Float14,369,000Market Cap$93.97 million OptionableNot Optionable Beta0.78 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Robert M. Hershberg M.D. (Age 62)Ph.D., President, CEO & Chairman of the Board Comp: $1.04MMr. Ozzie BergerSenior Vice President of Regulatory AffairsKey CompetitorsCabaletta BioNASDAQ:CABABlack Diamond TherapeuticsNASDAQ:BDTXScilexNASDAQ:SCLXSolid BiosciencesNASDAQ:SLDBPoseida TherapeuticsNASDAQ:PSTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 24,410 shares on 7/26/2024Ownership: 0.189%Aditya KohliSold 6,000 sharesTotal: $88,380.00 ($14.73/share)Aditya KohliSold 6,000 sharesTotal: $92,700.00 ($15.45/share)Tidal Investments LLCBought 12,465 shares on 5/17/2024Ownership: 0.025%California State Teachers Retirement SystemSold 1,510 shares on 5/16/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions HLVX Stock Analysis - Frequently Asked Questions How have HLVX shares performed this year? HilleVax's stock was trading at $16.05 at the beginning of the year. Since then, HLVX stock has decreased by 88.2% and is now trading at $1.89. View the best growth stocks for 2024 here. How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.13. When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share. Who are HilleVax's major shareholders? HilleVax's top institutional investors include Bank of New York Mellon Corp (0.19%). Insiders that own company stock include Life Sciences X LP Frazier, Aditya Kohli, Astrid Borkowski, Shane Maltbie and Sean Mcloughlin. View institutional ownership trends. How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HLVX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
